…GŒÆ›u››‘KŒâ‚è_cs1.indd
|
|
|
- なぎさ なぐも
- 7 years ago
- Views:
Transcription
1 a. b. c. d. e. 1-3 A. 4 B a. b. c. d. e a. b. c. d. e. 1-8 a. b. c. d. e A. 2 B. C a. /
2 2 b. / c. / d. / e. / 1-12 a. T b. c. M d. e Tim Schwartz a. b. g c. d. DPT e Eileen Ratamacher a. b. c. d. Clostridium difficile e a. b. c. d A. B. C C3 a. ic3 b. ic3b c. C3b d. ic3bb e. C3bBb 2-4 C3b CR1 2-5 H I
3 3 DAF MCP iii 2-6 A. 3 B. 3 a. b. c. d. e A. iii B. 2-7 A B A B a. 1. ic3b b. 2. c. CR3 3. d. CR4 4. e. CR1 5. f. TLR4 TLR4 6. g. TLR5 7. C3b h. TLR RNA 2-13 TNF-a a. b. IL-12 c. CXCL8 d. IL-1b e. IL A. B. C. 2-8 TLR5 TRL4 TLR1 TLR2 TLR2 TLR6 TLR3, 7, 8, TLR TLR 2-15 NK a. TNF-a b. c. d. e. IFN-g 2-10 TLR NFkB Jonathan Miller Jonathan
4 4 Neisseria meningitidis C3 B H a. C3 C3bBb b. C3 C3b c. d. e Mary Hason Staphylococcus aureus Mary a. NADPH b. IFN-b c. IL-6 d. TNF-a e a. b. c. d. e B T a. B b. B T c. d. B T e. T B 3-5 T a. b. c. d. e. 3-6 a. / /T b. / /B c. / /MHC d. / /T e. / /B 3-7 CD4 T CD8 T A B MHC
5 5 3-8 A. T 2 B. 3-9 A MHC B MHC T 3-10 a. IgG b. IgA B c. IgG d. IgD e. IgE 3-11 T 3-12 AB 3-13 IgM IgM 3-14 B Stephanie Goldstein 42 1 MRI Stephanie 1 a. T T b. B B c. d. T e. T T 4 B 4-1 A. B. 4-2 H L V C Fab Fc 4-3 a. b. c. d. e. 4-4 A. B. C. D.
6 6 4-5 T a. b. c. d. e. 4-6 A. V D J B. H V C. 4-7 H L a. D H J H b. V l J l c. D k V H d. V H J H e. V H D H 4-8 a. b. P N c. V D J d. e. 4-9 V D J 4-10 a. IgA IgD IgE IgG IgM 5 b. c. 4 H 4 L d. H L e. C 4-11 a. B b. H L N c. H L d. H C e. ll kl 4-12 a. B b. c. C d. AID e a. b. 1 c. B d. e.
7 H a. RNA b. c. d. e Aliya Agassi X 2 6 IgM IgA IgG IgA IgG IgM Aliya a. b. IgA c. X g d. e. X IgM f. AID g. 5-4 T CD3 z a. T b. MHC c. MHC d. CD4 CD8 e. T 5-5 T a. CD8 / / b. CD8 / B /B c. CD4 / / d. CD4 / B /B e. 5-6 RAG-1 RAG-2 SCID a. T b. T c. d. T e. T 5 T 5-1 T AB T a b TCRa TCRb H L 5-3 T 5-7 A. i MHC ii MHC MHC iii T iv B. MHC i iv 5-8 CD4 T MHC a. MHC CD4 CD8 b. b a c. MHC T
8 8 d. a b e. a b 5-9 A B C T 5-10 A. B. i MHC H a b 2 ii TAP 1 Brittany MHC CD8 T a. HLA-DM b. c. CLIP d. TAP-1 TAP-2 e. C TA MHC 5-11 MHC CLIP a. HLA-DM b. HLA-DO c. HLA-DP d. HLA-DQ e. HLA-DR 5-12 A. B. i ii HLA- DM 5-13 A. MHC B. T MHC iii 5-14 MHC DNA 6 B 6-1 B a. b. c. d. e. f. 6-2 B a. B b. B c. B d. e. B f. B 6-3 A. B B. B IL Brittany Hudson 6-4 A. B 2
9 9 B. i H L ii B C. 1 H 1 L B TdT 6-6 B mh a. RAG b. H c. RAG-1 RAG-2 d. 2 mh e. 6-7 A. B-2 B-1 B. B-1 d. B e. B 6-10 B a. / b. / c. / d. / e. / 6-11 B 6-12 a. b c. MHC d. e. 6-8 a. b. c. d. e. MHC 6-9 B a. b. c. B B 6-13 A. B B B A. B B B. B B
10 /ml /ml 2,800 /ml 5,000 /ml 30 mm/h 20 mm/h IgG 4,500 mg/dl 600 1,500 mg/dl IgA IgM 75 L IgG l a. IgG b. c. d. IgG IgG1 IgG2 IgG3 IgG4 e. kl ll c. d. e. 7-4 ab T T MHC a. b. c. 2 b d. CD4 T e. CD8 T 7 T 7-1 B L VpreB l5 L m B T VpreB l5 7-6 MHC A. B. C. MHC 7-2 T a. g d b. b c. a b d. a g d e. b g d 7-3 T a. b. 7-7 T a 2 T A. 2 B. 2 C. 2 T 7-8 B
11 11 T 7-9 MHC MHC HLA-DP DQ DR A. MHC B. g 7-10 T A. T T B. B 7-11 A. 2 B A. T T reg B. T reg CD4 T 7-13 a. T T b. T B c. 30 d. T e AIRE a. b. APECED c. SCID d. MHC e. MHC 7-15 Giulia McGettigan 48 X CD4 CD8 T B in situ 22 Giulia a. AIDS b. c. d. e. IgM 8 T 8-1 A. T B. iii iii C. T D. T 8-2 T
12 A. T B. T HEV 8-4 T a. MHC b. c. d. e. 8-5 A. T B. T C. T 8-6 a. / b. / CD28 c. T /MHC d. T /T e. / ITAM T A. 3 B. C. 8-8 T A. T B. T 8-9 T T reg a. T reg CD8 b. T reg CD25 IL-2 a IFN-g c. T reg T reg d. T reg T e. T reg TGF-b T 8-10 T i CD3 ii Lckiii CD45iv ZAP-70v z viip 3 vii 8-11 T a. B7 b. IL-2 c. T d. T e. ITAM 8-12 A.
13 13 B. C. d. e A T T IL-2 IL-2 a 8-14 B CD4 T H 2 CD4 T H 2 A. B. B IgG Angelina Roebuck Angelina a. CD40 b. c. CD95 Fas d. IL-2 e. CD Vijay Kumar T IL-4 IL-5 IL-10 a. b. c. 9 B 9-1 B B B 9-2 A. TD TI B. TI-1 T B C. TI-2 T B D. TI-1 T 9-3 A. B. IgM T CD40 C. ADCC NK NK Fc D. TI T CD40 T
14 a. b. B c. d. CR2 e. B f. B 9-6 A. IgM B. IgM iii iii 9-7 A. Ig IgA B. IgA 9-11 A. B. iii C IgA 9-13 IgE A. IgG4 2 bispecificity B A. FcRn IgG B. IgG 9-9 A. FceR NK FcgR B B T Amanda Chenoweth C3 a. b. c. d. e.
15 AB T A. B B 2 B. T T B B A B B 10-4 AB AB 10-5 T T T 10-6 IgA 4 IgA NK A. NK B. NK C. NK NK MHC D. NK 10-8 IgA 10-9 T H A. NK CD94 NKG2A B. CD94 NKG2A MHC C. NK CD94 NKG2A MHC
16 Fatima Ahmed 38 Samir Fatima 18 Fatima RhoGAM a. Fatima Rh Rh b. Fatima Rh Rh c. Fatima Rh Samir Rh d. Samir Rh Rh e. Fatima Rh Rh A. B A. B. C. D , A B 11-5 CD8 T a. LFA-3 b. Toll TLR c. TAP d. MHC e. MHC 11-6 A. 2 i ii 11-4 A a. b. c. d. 1 e. RNA RNA f. g. h. i. j. T B 1. Staphylococcus aureus 2. Toxoplasma gondii 3. Salmonella typhimurium 4. influenza virus 5. Mycobacterium tuberculosis 6. varicella-zoster virus 7. Neisseria gonorrhoeae 8. Treponema pallidum 9. Listeria monocytogenes 10. herpes simplex virus
17 17 B A. C3 C4 B. C. C5 C A. 3 B. NADPH C A. IL-2 IL-4 IL-7 g g c B. Jak3 C A. HIV B. HIV HIV HIV C. HIV A. HIV seroconversion B. HIV HIV HIV Christiana Carter ST 3 CT Mycobacterium fortuitum HIV ELISA PCR Christiana IFN-g LPSTNF-a 2 a. b. c. IFN-g d. X g e Doug Perkins Doug A b a. T T
18 18 b. T c. MHC d. B e. MHC CD8 T A B A B a. 1. B b. 2. IgE c. 3. CD8 T d CD4 T IgG A. B A. B 3 B A 2 B 12-7 A. B. C A. B. C MHC T H 1 T H 2 A. B. T
19 Anita Garcia Rosa Rosario Rosa Anita 2 Anita a. b. c. d. e Anita George Cunningham 23 George TNF-a TNF-a 12 a. b. c. d. CD8 T e Anders Anderson Anders 5 Anders a. b. c. IgA d. e A. B a. b. c. T d. T e. T f. B g. AIRE h. i. j. k. T A B C
20 a. IgG b. IgG c. T d. T e A. APECED B. APECED in vitro T A. B HLA-DQ2 HLA-DQ8 HLA- DQ2 HLA-DQ8 1 A. B A. B HLA-DRB T CD25 CD4 T A B 13-3 A B C a. b. c. d. e. f. g. 1 h. i DNAsnRNP scrnp IgG Rh 9. b A. B. C. b D. E. F. G. H. I.
21 a. TNF-a b. C c. CD20 d. e. CD Lisa Montague Lisa Lisa a. b. c. d. e. Rh a. b. c. d. e a. b. MHC c. d. e A. B ABC DE 14-7 A. B. C A. B. C Madison Tavistock The Wee Folks Daycare Facility 1 9 MMR 3 DPT
22 22 MMR Madison a. Madison b. Madison c. DPT d. e. MMR Madison Jenny O Mara 5 Jenny 2 a. IgA b. IgM c. IgG d. IgM e. IgG CDC 2 3 PCR DNA a. Bacillus anthracis b. Corynebacterium diphteriae c. Yersinia pestis d. e. Clostridium botulinum a. b. c. d. e A. AB O HLA B. ABO C. D MHC T
23 23 MHC A. 3 B A 15-9 a. T b. T c. A B O d. Rh rhesus e. NK ADCC A. MoAb B HLA a. T b. MHC T MHC c. T HLA d. HLA e. HLA T A. HLA B. T A. B a. ABO Rh T b. ABO Rh c. DNA d. HLA e Carter Petersen HLA 25 A a. b.
24 24 c. d. e Richard French Don HLA Richard T T a. T T b. T c. Don HLA d. Don T e. T Danielle Bouvier HLA HLA-A: 0101/0301 HLA-B: 0702/0801 HLA-DRB1: 0301/0701 a. A: 0301/0201 B: 4402/0801 DRB1: 0301/0403 b. A: 0301/2902 B: 1801/0801 DRB1: 0301/0701 c. A: 2902/0201 B: 0702/0801 DRB1: 0301/13011 d. A: 0101/0101 B: 5701/0801 DRB1: 0701/0701 e. A: 0101/0301 B: 0702/5701 DRBA: 0403/ A. B. C a. b. c. d. e. f in vitro A. 2 B A. B. C A. B.
25 A. NK gd T CD8 T B AB T A B a. b. c. d. e A. B Lauren Brooks a. BCG b. c. IL-10 d. IL-13 e. BCG MIC
MHC23-3
Major Histocompatibility Complex 2016; 23 (3): 168 184 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA 11 25 28 10 22 1 4 61 44 6 1 10 11 5 HLA 60 3 27 3 5 9 5 10 19 5 50 22.4 5.9 8.2% 78.7%
2つの疑問
Daiichi College of Pharmaceutical Sciences 22-1 Tamagawa-cho, Minami-ku,Fukuoka 815-8511, Japan 1. B 10 14 2 2. 1. 2. 3. G. Edelman 3. H (heavy chain) L (light chain) 2 4 S-S R. Porter papain) N Fab(Fragment
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 () - 1 - - 2 - - 3 - - 4 - - 5 - 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
i ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
28 2 16 学 説 試 験 問 題 (A) 80 2 81 81 のうち を 横 線 で 81 とマークすれば 良 い HB 良 い 例 悪 い 例 1 a b c d e 2 a b c d e 3 a A b c d e 4 a b c d e 5 a b c d e 6 a b c d e T 7 a b c d e 嗉 8 9 a b c d e 10 a b c % d e B 11
untitled
28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS
-51-
-50- -51- 11 3 28 8 1 24 7 2 36 10 1-52- -53- 1 2-54- 6 1 2 3 4 5 6 6 1 19 5 200 300ml 20 6 400ml -55- -56- 10-57- 4 2 20-58- 2,500-59- -60- -61- 2-62- 6 3-63- 9 68 1 6-64- 3-65- 4-66- 5 6-67- -68- 1 1
2
1 2 3 4 5 6 7 8 9 10 I II III 11 IV 12 V 13 VI VII 14 VIII. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 _ 33 _ 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 VII 51 52 53 54 55 56 57 58 59
untitled
i ii iii iv v 43 43 vi 43 vii T+1 T+2 1 viii 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 a) ( ) b) ( ) 51
Major Histocompatibility Complex 2018; 25 (2): 抄録集 2 HLA A 3 128
Major Histocompatibility Complex 2018; 25 (: 128 138 抄録集 2018 4 14 A 3 128 MHC 2018; 25 ( HLA 2013 10.5 10 8 12 10 8 2016 CD34 + HLA NC 10 8 CD34 + CD34 + 10 6 NC10.5 2013.Apr 2014.Mar NC11 2014.Apr 2016.Jun
110
109 110 111 112 113 KT ST 15L90L 90Y45Y W45L 90LO 114 115 K20 DR MH MHH 116 117 118 119 150 165.7 1105 154 197 200 216.9 13510 202 254 250 268.1 15510 250 319 300 319.3 17510 298 370 150 165.7 1105 154
M41 JP Manual.indd
i ii iii iv v vi vii 1 No / A-B EQ 2 MIC REC REC00001.WAV Stereo CH:01 0:00:00 1:50:00 3 4 5 6 7 8 9 10 11 12 1 1 F F A A 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 Φ 35 36 37 38
入門ガイド
ii iii iv NEC Corporation 1998 v P A R 1 P A R 2 P A R 3 T T T vi P A R T 4 P A R T 5 P A R T 6 P A R T 7 vii 1P A R T 1 2 2 1 3 1 4 1 1 5 2 3 6 4 1 7 1 2 3 8 1 1 2 3 9 1 2 10 1 1 2 11 3 12 1 2 1 3 4 13
104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26
25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (
2006年3月8日
18 21 1990 2004 2 2005 14 15 2004 1990 2005 2003 300 7 2 1 2005 1972 100 40 6 1972 2004 197 6,500 2004 21 59 100 65 2007 5 2005 30 1.8 535.89 348.33 187.56 2006 2006 5 1 30 1 30 46 46 1 46 1000kl 4 1 100kl
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
SC-85X2取説
I II III IV V VI .................. VII VIII IX X 1-1 1-2 1-3 1-4 ( ) 1-5 1-6 2-1 2-2 3-1 3-2 3-3 8 3-4 3-5 3-6 3-7 ) ) - - 3-8 3-9 4-1 4-2 4-3 4-4 4-5 4-6 5-1 5-2 5-3 5-4 5-5 5-6 5-7 5-8 5-9 5-10 5-11
<4D6963726F736F667420506F776572506F696E74202D208376838C835B83938365815B835683878393312E707074205B8CDD8AB78382815B83685D>
i i vi ii iii iv v vi vii viii ix 2 3 4 5 6 7 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
第１部 一般的コメント
(( 2000 11 24 2003 12 31 3122 94 2332 508 26 a () () i ii iii iv (i) (ii) (i) (ii) (iii) (iv) (a) (b)(c)(d) a) / (i) (ii) (iii) (iv) 1996 7 1996 12
表1票4.qx4
iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614
第１章 国民年金における無年金
1 2 3 4 ILO ILO 5 i ii 6 7 8 9 10 ( ) 3 2 ( ) 3 2 2 2 11 20 60 12 1 2 3 4 5 6 7 8 9 10 11 12 13 13 14 15 16 17 14 15 8 16 2003 1 17 18 iii 19 iv 20 21 22 23 24 25 ,,, 26 27 28 29 30 (1) (2) (3) 31 1 20
MHC 2013; 20 (1) 11 参加費 1 2, , ,000 会議等 :50 14: :30 13: :00 会場地図 参天製薬株式会社本社案内図 TEL 新大阪駅より
Major Histocompatibility Complex 2013; 20 (1): 63 89 抄録集 11 2013 2 2 3 9 19 TEL: 06 6321 7000 630 0293 1248 1 TEL: 0743 77 0880 E-mail: tubaki@nara.med.kindai.ac.jp 63 MHC 2013; 20 (1) 11 参加費 1 2,000 2
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
合併後の交付税について
(1) (2) 1 0.9 0.7 0.5 0.3 0.1 2 3 (1) (a), 4 (b) (a), (c) (a) 0.9 0.7 0.5 0.3 0.1 (b) (d),(e) (f) (g) (h) (a) (i) (g) (h) (j) (i) 5 (2) 6 (3) (A) (B) (A)+(B) n 1,000 1,000 2,000 n+1 970 970 1,940 3.0%
これわかWord2010_第1部_100710.indd
i 1 1 2 3 6 6 7 8 10 10 11 12 12 12 13 2 15 15 16 17 17 18 19 20 20 21 ii CONTENTS 25 26 26 28 28 29 30 30 31 32 35 35 35 36 37 40 42 44 44 45 46 49 50 50 51 iii 52 52 52 53 55 56 56 57 58 58 60 60 iv
パワポカバー入稿用.indd
i 1 1 2 2 3 3 4 4 4 5 7 8 8 9 9 10 11 13 14 15 16 17 19 ii CONTENTS 2 21 21 22 25 26 32 37 38 39 39 41 41 43 43 43 44 45 46 47 47 49 52 54 56 56 iii 57 59 62 64 64 66 67 68 71 72 72 73 74 74 77 79 81 84
これでわかるAccess2010
i 1 1 1 2 2 2 3 4 4 5 6 7 7 9 10 11 12 13 14 15 17 ii CONTENTS 2 19 19 20 23 24 25 25 26 29 29 31 31 33 35 36 36 39 39 41 44 45 46 48 iii 50 50 52 54 55 57 57 59 61 63 64 66 66 67 70 70 73 74 74 77 77
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
平成18年版 男女共同参画白書
i ii iii iv v vi vii viii ix 3 4 5 6 7 8 9 Column 10 11 12 13 14 15 Column 16 17 18 19 20 21 22 23 24 25 26 Column 27 28 29 30 Column 31 32 33 34 35 36 Column 37 Column 38 39 40 Column 41 42 43 44 45
リサイクルデータブック2016
AppendixEU SDGs2159EU 21512UNEPOECD2165G7 2165 213 Appendix 1 EU 2 EU 3 215 i CONTENTS i 1 213 1 213 2 1 4 2 2 6 3 3 6 4 213 7 4 5 9 6 213 9 5 7 1 8 213 1 9 11 1 213 11 11 213 11 6 6.1 12 213 14 6.2 13
provider_020524_2.PDF
1 1 1 2 2 3 (1) 3 (2) 4 (3) 6 7 7 (1) 8 (2) 21 26 27 27 27 28 31 32 32 36 1 1 2 2 (1) 3 3 4 45 (2) 6 7 5 (3) 6 7 8 (1) ii iii iv 8 * 9 10 11 9 12 10 13 14 15 11 16 17 12 13 18 19 20 (2) 14 21 22 23 24
E. coli E. coli é H. influenzae Helicobacter pylori
é C.pneumoniae C.trachomatis C.trachomatis 1 é Chlamydia pneumoniae Chlamydia psittaci Chlamydia trachomatis 3 E. coli E. coli é H. influenzae Helicobacter pylori K. pneumoniae L. monocytogenes ü l Staphylococcus
「産業上利用することができる発明」の審査の運用指針（案）
1 1.... 2 1.1... 2 2.... 4 2.1... 4 3.... 6 4.... 6 1 1 29 1 29 1 1 1. 2 1 1.1 (1) (2) (3) 1 (4) 2 4 1 2 2 3 4 31 12 5 7 2.2 (5) ( a ) ( b ) 1 3 2 ( c ) (6) 2. 2.1 2.1 (1) 4 ( i ) ( ii ) ( iii ) ( iv)
16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57
Major Histocompatibility Complex 2018; 25 (1): 56 82 抄録集 16 2018 3 3 7 2 4 43 TEL 06 6962 7001 594 1101 840 TEL 0725 56 1220 56 16 MHC 2018; 25 (1) 参加費 1 2,000 2 1,000 3 3,000 会議等 1 3 3 13:00 13:10 2 3
取扱説明書 ［F-02F］
F-02F 4. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d a b cd 9 e a b c d e 20 2 22 ab a b 23 a b 24 c d e 25 26 o a b c p q r s t u v w d h i j k l e f g d m n a b c d e f g h i j k l m n x 27 o
エクセルカバー入稿用.indd
i 1 1 2 3 5 5 6 7 7 8 9 9 10 11 11 11 12 2 13 13 14 15 15 16 17 17 ii CONTENTS 18 18 21 22 22 24 25 26 27 27 28 29 30 31 32 36 37 40 40 42 43 44 44 46 47 48 iii 48 50 51 52 54 55 59 61 62 64 65 66 67 68
1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30
1 2420128 1 6 3 2 199103 189/1 1991031891 3 4 5 JISJIS X 0208, 1997 1 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30 1 3 5 7 6 7
:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
ii iii iv CON T E N T S iii iv v Chapter1 Chapter2 Chapter 1 002 1.1 004 1.2 004 1.2.1 007 1.2.2 009 1.3 009 1.3.1 010 1.3.2 012 1.4 012 1.4.1 014 1.4.2 015 1.5 Chapter3 Chapter4 Chapter5 Chapter6 Chapter7
BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG , ,000 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mous
Bio X Cell 社価格表 (2018 年 4 月 ) < 株式会社シン コーポレーション > Bio X Cell 社価格表 (2018 年 4 月 ) ご注文ごとに別途取扱手数料 (2( 万円 税別 ) を申し受けます 大学向け価格でのご購入には アカデミックプライス適用申込書のご提出が必須となります 品番クローン品名イソタイプ 容量 (mg) 大学向希望小売価格 ( 円 ) 税別 希望小売価格
01_.g.r..
I II III IV V VI VII VIII IX X XI I II III IV V I I I II II II I I YS-1 I YS-2 I YS-3 I YS-4 I YS-5 I YS-6 I YS-7 II II YS-1 II YS-2 II YS-3 II YS-4 II YS-5 II YS-6 II YS-7 III III YS-1 III YS-2
178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21
I 178 II 180 III ( ) 181 IV 183 V 185 VI 186 178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21 4 10 (
untitled
I...1 II...2...2 III...3...3...7 IV...15...15...20 V...23...23...24...25 VI...31...31...32...33...40...47 VII...62...62...67 VIII...70 1 2 3 4 m 3 m 3 m 3 m 3 m 3 m 3 5 6 () 17 18 7 () 17 () 17 8 9 ()
DynalTransplantDiagnostic.indd
2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing
LABIO21_5
2001 4 5 8 21 14 17 Helicobacter hepaticus H.rodentium H.bilis Pasteurella multocida P.multocida Pasteurella multocida Rattus norvegicus 2 21 25 27 28 28 29 30 LABIO 21 JULY 2001 3 LABIO 21 JULY 2001 4
活用ガイド （ソフトウェア編）
(Windows 95 ) ii iii iv NEC Corporation 1999 v P A R T 1 vi P A R T 2 vii P A R T 3 P A R T 4 viii P A R T 5 ix x P A R T 1 2 3 1 1 2 4 1 2 3 4 5 1 1 2 3 4 6 5 6 7 7 1 1 2 8 1 9 1 1 2 3 4 5 6 1 2 3 4
3 5 18 3 5000 1 2 7 8 120 1 9 1954 29 18 12 30 700 4km 1.5 100 50 6 13 5 99 93 34 17 2 2002 04 14 16 6000 12 57 60 1986 55 3 3 3 500 350 4 5 250 18 19 1590 1591 250 100 500 20 800 20 55 3 3 3 18 19 1590
困ったときのQ&A
ii iii iv NEC Corporation 1997 v P A R T 1 vi vii P A R T 2 viii P A R T 3 ix x xi 1P A R T 2 1 3 4 1 5 6 1 7 8 1 9 1 2 3 4 10 1 11 12 1 13 14 1 1 2 15 16 1 2 1 1 2 3 4 5 17 18 1 2 3 1 19 20 1 21 22 1
H26分子遺伝-22（免疫不全症）.ppt
第 22 回 免疫不全症 1. 原発性免疫不全症候群 2. 後天性免疫不全症候群 2014 年 11 月 19 日 免疫不全 " II" 原発性 ( 先天性 ) 免疫不全 + 続発性免疫不全 疾患の総称 原発性免疫不全症候群 抗体産生不全を主とする疾患 (47.3%)" 細胞性免疫不全を主とする疾患 ( 複合免疫不全症 ) (10.3%)" 明確に定義された免疫不全症 (17.8%);AT WAS
Shigella Tenesmus DHL E. coli SIM M S. dysenteriae A S. flexneri B S. boydii C S. sonnei D Salmonella Salmonella 2 S. enterica 6 S. enter
by Kazacky 2007 3 12 1 1.1 1.1.1 Enterobacteriaceae Vibrionaceae Pasteurellaceae Enterobacteriaceae Escherichia Shigella Salmonella Yersinia Klebsiella Proteus Serratia Escherichia E. coli O LPS H EPEC;
III
III 1 1 2 1 2 3 1 3 4 1 3 1 4 1 3 2 4 1 3 3 6 1 4 6 1 4 1 6 1 4 2 8 1 4 3 9 1 5 10 1 5 1 10 1 5 2 12 1 5 3 12 1 5 4 13 1 6 15 2 1 18 2 1 1 18 2 1 2 19 2 2 20 2 3 22 2 3 1 22 2 3 2 24 2 4 25 2 4 1 25 2
iii iv v vi vii viii ix 1 1-1 1-2 1-3 2 2-1 3 3-1 3-2 3-3 3-4 4 4-1 4-2 5 5-1 5-2 5-3 5-4 5-5 5-6 5-7 6 6-1 6-2 6-3 6-4 6-5 6 6-1 6-2 6-3 6-4 6-5 7 7-1 7-2 7-3 7-4 7-5 7-6 7-7 7-8 7-9 7-10 7-11 8 8-1
in situ Hex
in situ Hex Sox Sox17Sox18 Sry Sox9 Sox17 Hex Hex N Drosophila O The 5th Conference on ABC Proteins and Ion Channels From Gene to Disease The 5th Conference on ABC Proteins and Ion Channels From Gene
中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
活用ガイド （ソフトウェア編）
(Windows 98 ) ii iii iv v NEC Corporation 1999 vi P A R T 1 P A R T 2 vii P A R T 3 viii P A R T 4 ix P A R T 5 x P A R T 1 2 3 1 1 2 4 1 2 3 4 5 1 1 2 3 4 5 6 6 7 7 1 1 2 8 1 9 1 1 2 3 4 5 6 1 2 3 10
i
i ii iii iv v vi vii viii ix x xi ( ) 854.3 700.9 10 200 3,126.9 162.3 100.6 18.3 26.5 5.6/s ( ) ( ) 1949 8 12 () () ア イ ウ ) ) () () () () BC () () (
untitled
( ) 200133 3 3 3 3, 7 347 57 10 i ii iii -1- -2- -3- -4- 90011001700mm -5- 4.2 1991 73.5 44.4 7.4 10.5 10.5 7.4 W 3 H 2.25 H 2.25 7.4 51.8 140.6 88.8 268.8m 5,037.9m 2 2mm 16cm916cm 10.5 W 3 H 2.25 62.8
リサイクルデータブック2017
AppendixEU SDGs2159EU 21512UNEPOECD2165G7 2165 214 Appendix 1 EU 2 EU EU( EU EU EU EU 3 217 i CONTENTS i 1 214 1 214 2 1 4 2 2 6 3 3 6 4 214 7 4 5 9 6 214 9 5 7 1 8 214 1 9 11 1 214 11 11 214 11 6 6.1
... a. b. c. a b c : - a b iphone CD DVD a, b 2
. a. b. c. a b a,b c a,b c a b c ab,c a-ca a a-c 1 ... a. b. c. a b c : - a b iphone CD DVD a, b 2 c : - : -.. a-c a. b. i ii iii iv v c. d. a 3 : b. i v i ii iii iv negligence v conspiracy of silence
AccessflÌfl—−ÇŠš1
ACCESS ACCESS i ii ACCESS iii iv ACCESS v vi ACCESS CONTENTS ACCESS CONTENTS ACCESS 1 ACCESS 1 2 ACCESS 3 1 4 ACCESS 5 1 6 ACCESS 7 1 8 9 ACCESS 10 1 ACCESS 11 1 12 ACCESS 13 1 14 ACCESS 15 1 v 16 ACCESS
CRS4
I... 1 II... 1 A... 1 B... 1 C... 1 D... 2 E... 3 III... 3 A... 3 B... 4 C... 5 IV... 8 A... 8 B... 8 C... 9 D... 10 V... 11 A... 11 B... 11 C... 12 VI... 12 A... 12 B... 12 C... 12 VII... 13 ii I II A
活用ガイド (ソフトウェア編)
ii iii iv NEC Corporation 1998 v vi PA RT 1 vii PA RT 2 viii PA RT 3 PA RT 4 ix P A R T 1 2 3 1 4 5 1 1 2 1 2 3 4 6 1 2 3 4 5 7 1 6 7 8 1 9 1 10 1 2 3 4 5 6 7 8 9 10 11 11 1 12 12 1 13 1 1 14 2 3 4 5 1
１
10 200 15 20 50 (1) (2) 45 A4 JICA 15 WS 1 [] a. b. 10 A 30 15 15 NGO PC 5 15 15 15 15 NGO 1948 1970 10 NGO 90 AB 40 40 WS 1 NGO 40 WS Q 43 63 73 15 9 8 5 5 4 63 17 9 8 6 6 4 2000 14 15 100 2000 1
051
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT June THE JAPANESE JOURNAL OF ANTIBIOTICS
パソコン機能ガイド
PART12 ii iii iv v 1 2 3 4 5 vi vii viii ix P A R T 1 x P A R T 2 xi P A R T 3 xii xiii P A R T 1 2 3 1 4 5 1 6 1 1 2 7 1 2 8 1 9 10 1 11 12 1 13 1 2 3 4 14 1 15 1 2 3 16 4 1 1 2 3 17 18 1 19 20 1 1
パソコン機能ガイド
PART2 iii ii iv v 1 2 3 4 5 vi vii viii ix P A R T 1 x P A R T 2 xi P A R T 3 xii xiii P A R T 1 2 1 3 4 1 5 6 1 2 1 1 2 7 8 9 1 10 1 11 12 1 13 1 2 3 14 4 1 1 2 3 15 16 1 17 1 18 1 1 2 19 20 1 21 1 22
1... 1 2... 1 1... 1 2... 2 3... 2 4... 4 5... 4 6... 4 7... 22 8... 22 3... 22 1... 22 2... 23 3... 23 4... 24 5... 24 6... 25 7... 31 8... 32 9... 3
3 2620149 3 6 3 2 198812 21/ 198812 21 1 3 4 5 JISJIS X 0208 : 1997 JIS 4 JIS X 0213:2004 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1 2... 1 1... 1 2... 2 3... 2 4... 4 5... 4 6... 4 7... 22
262014 3 1 1 6 3 2 198810 2/ 198810 2 1 3 4 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 2... 2... 4... 5... 9... 9... 10... 10... 10... 10... 13 2... 13 3... 15... 15... 15... 16 4...
